Mesa Laboratories, Inc.
NASDAQ:MLABHardware, Equipment & Parts
-$0.15 today
- Market cap
- $774.56M
- Beta
- 0.93
- P/E (TTM)
- 78.3
- EPS (TTM)
- $1.21
- Dividend yield
- 0.68%
Volume 0.07M
Average 0.16M
MLAB Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Mesa Laboratories, Inc.NASDAQ: MLAB
Free Cash Flow · Q4 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q4 FY2026 free cash flow of $16.8M rose 44.1% year over year, ahead of the +1.2% change in trailing-twelve-month free cash flow. Sequentially, it fell 6.8% from the prior quarter. Over 3 fiscal years it compounded at +19.1% a year.
Context
- Free cash flow amounted to 15.9% of revenue in FY2026, down 1.7 pp from a year earlier.
- Free cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +44.1% holds above the trailing-twelve-month pace of +1.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2026
- 39.58M USD
- Year-over-year change
- -6.4%
- 4-year CAGR
- +3.3%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 39.58M | -6.4% |
| FY2025 | 2025-03-31 | 42.31M | +1.8% |
| FY2024 | 2024-03-31 | 41.57M | +77.3% |
| FY2023 | 2023-03-31 | 23.44M | -32.6% |
| FY2022 | 2022-03-31 | 34.79M | — |
Free Cash Flow vs competitors
How MLAB compares with its peers on the latest reported figures
- MLAB's LTM Mar 2026 free cash flow of $42.83M is the 10th largest of the 11 companies compared; the peer median is $330.65M.
- Its year-over-year change of +1.2% is the 7th highest of 11, against a peer median of +6.4%.
- Free cash flow amounts to 17.2% of revenue for MLAB, versus a peer median of 19.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $7.6B | +24.3% | -3.1% | 16.0% | |
| LTM Jul 2026 | $1.27B | +16.5% | +4.1% | 17.2% | |
| LTM Jul 2026 | $559.34M | +11.2% | -5.1% | 19.2% | |
| LTM Jun 2026 | $447.7M | -9.8% | -7.1% | 21.3% | |
| LTM Jun 2026 | $353.1M | +1.6% | +67.1% | 13.6% | |
| LTM Sep 2026 | $308.2M | +37.6% | +6.8% | 25.1% | |
| LTM Jun 2026 | $121.44M | +113.5% | — | 19.7% | |
| LTM Mar 2026 | $116.21M | -36.5% | -25.9% | 72.6% | |
| LTM Mar 2026 | $94.48M | -23.7% | -3.9% | 109.5% | |
| LTM Mar 2026 | $42.83M | +1.2% | +19.1% | 17.2% | |
| LTM Jun 2026 | $35.11M | -21.5% | — | 16.8% | |
| Peer median (excluding MLAB) | $330.65M | +6.4% | -3.5% | 19.4% | |
Competitors are the stored peer set for MLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | 1.87M | 930K | (254.25M) | (1.97M) | 6.71M |
| Depreciation & Amortization | 25.07M | 33.13M | 31.57M | 24.53M | 23.27M |
| Deferred Income Tax | 128K | (3.49M) | (28.42M) | (72K) | (1.29M) |
| Stock-Based Compensation | 11.39M | 12.54M | 11.94M | 13.14M | 17.87M |
| Change in Working Capital | (7.19M) | (17.11M) | 5.97M | 6.9M | (4.99M) |
| Accounts Receivables | (6.75M) | (2.12M) | 4.94M | (2.93M) | (3.21M) |
| Inventory | (1.05M) | (10.18M) | 2.56M | 1.15M | (4.43M) |
| Accounts Payables | 1.37M | (1.55M) | (97K) | (388K) | (1.2M) |
| Other Working Capital | (765K) | (3.26M) | (1.43M) | 9.06M | 3.85M |
| Other Non-Cash Items | 7.96M | 1.99M | 277.32M | 4.28M | 1.26M |
| Operating Cash Flow | 39.22M | 27.98M | 44.13M | 46.81M | 42.83M |
| Capital Expenditures | (4.43M) | (4.54M) | (2.57M) | (4.5M) | (3.25M) |
| Acquisitions (Net) | (300.79M) | (4.95M) | (78.74M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | (250K) | 0 |
| Investing Cash Flow | (305.23M) | (9.49M) | (81.31M) | (4.5M) | (3.25M) |
| Debt Repayment | 49M | (36M) | 37.5M | (42.35M) | (26.75M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (3.34M) | (3.41M) | (3.45M) | (3.47M) | (3.52M) |
| Other Financing Activities | 6.92M | 6.08M | (1.22M) | 1.31M | (11.58M) |
| Financing Cash Flow | 52.58M | (33.33M) | 32.84M | (44.51M) | (41.85M) |
| Effect of Forex Changes | (1.09M) | (1.6M) | (359K) | 1.31M | 1.88M |
| Net Change in Cash | (214.52M) | (16.44M) | (4.7M) | (893K) | (393K) |
| Free Cash Flow | 34.79M | 23.44M | 41.57M | 42.31M | 39.58M |
Mesa Laboratories, Inc.
NASDAQ:MLAB
Intrinsic Alpha fair value
Locked
Current Price
$137.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.